Article

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single center study

2024-07-15

Abstract excerpt

<h4>Background</h4> Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19 Data concerning early combined use of antivirals and monoclonal antibodies in this population are scarce. <h4>Research design and methods</h4> We performed an observational, prospective study, enrolling immunocompromised outpatient adults with mild-to-moderate COVID-19 treated with a combination of sotrovima...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2fdbf321-7878-5637-95e3-d32537196976
DOI: 10.1101/2024.07.15.24310384

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single center studyDOI 10.1101/2024.07.15.24310384Read

Early combination with remdesivir, nirmatrelvir/ritonavir and sotrovimab for the treatment of COVID-19 in immunocompromised hostsSemantic proximity Read

Effectiveness and Tolerability of Early Treatment with Monoclonal Antibodies against SARS-Cov-2: Results from A Real-Life Study before Omicron SurgeSemantic proximity Read

Persistent SARS-CoV-2 PCR positivity despite treatment in immunodeficient patientsSemantic proximity Read

Real-world Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the United StatesSemantic proximity Read

Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in EnglandSemantic proximity Read

REGEN-COV antibody cocktail (casirivimab/imdevimab) for the treatment of inpatients with early hospital-acquired COVID-19: a single center experienceSemantic proximity Read

Efficacy of late-onset antiviral treatment in immune-compromised hosts with persistent SARS-CoV-2 infectionSemantic proximity Read

Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron Variant of ConcernSemantic proximity Read

Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron SurgeSemantic proximity Read

Clinical evidence of the effectiveness of remdesivir in COVID-19 during periods dominated by Delta and Omicron SARS-CoV-2 variants.Semantic proximity Read

REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 OutpatientsSemantic proximity Read